Literature DB >> 12034366

Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases.

Takahito Nishiyama1, Kenichiro Ogura, Hiroaki Nakano, Tomokazu Ohnuma, Teppei Kaku, Akira Hiratsuka, Kei Muro, Tadashi Watabe.   

Abstract

The phenolic active metabolites, cis-4-hydroxytamoxifen (cis-HO-TAM) and trans-4-hydroxytamoxifen (trans-HO-TAM), of the anti-breast-cancer drug, trans-tamoxifen (TAM), were geometrically selectively glucuronidated in the manner of cis>>trans by microsomes and sulfated in the manner of trans>>cis by cytosol from the liver of 10 human subjects (7 females and 3 males). There was a large individual difference in the microsomal glucuronidation of cis-HO-TAM, which correlated well with glucuronidation of 4-hydroxybiphenyl by human liver microsomes. However, there was only a slight correlation between the glucuronidation of cis-HO-TAM and trans-HO-TAM or 4-nitrophenol (NP). A small individual difference was observed for the human liver cytosolic sulfation of trans-HO-TAM, which correlated well with the sulfation of NP. Recombinant human UDP-glucuronosyltransferase (UGT)2B15 catalyzed the cis-selective glucuronidation of geometrical isomers of HO-TAM. UGTs1A1, 1A4, 1A9 and 2B7 had weak activity toward HO-TAMs with a much smaller cis-selectivity than did UGT2B15. UGTs1A3 and 1A6 had no detectable activity toward these substrates. Among the four known major sulfotransferases (SULTs) occurring in the human liver, SULT1A1 was strongly suggested to play the most important role in the hepatic cytosolic trans-selective sulfation of HO-TAM isomers. A good correlation was observed between the hepatic cytosolic sulfation of trans-HO-TAM and NP, a standard substrate for SULT1A1. SULT1E1 had slight activity toward the HO-TAMs. SULTs1A3 and 2A1 had no detectable activity toward HO-TAMs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034366     DOI: 10.1016/s0006-2952(02)00994-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  31 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.

Authors:  Ann M Moyer; Vera J Suman; Richard M Weinshilboum; Rajeswari Avula; John L Black; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; James N Ingle; Matthew P Goetz
Journal:  Pharmacogenomics       Date:  2011-10-03       Impact factor: 2.533

Review 3.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Håvard Søiland; Jennifer Gjerde; Jens Peter Garne; Carol L Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

Review 5.  Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

6.  Human hepatic UGT2B15 developmental expression.

Authors:  Karthika Divakaran; Ronald N Hines; D Gail McCarver
Journal:  Toxicol Sci       Date:  2014-06-30       Impact factor: 4.849

7.  Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.

Authors:  Jennifer Gjerde; Jürgen Geisler; Steinar Lundgren; Dagfinn Ekse; Jan Erik Varhaug; Gunnar Mellgren; Vidar M Steen; Ernst A Lien
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

Review 8.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

9.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.

Authors:  Philip Lazarus; Dongxiao Sun
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

10.  In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Irma Meijerman; Ignasio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.